Patients with relapsing-remitting multiple sclerosis ( age 18-65 years , with Expanded Disability Status Scale score 5 ) were randomly assigned ( 1:1:1 ) via an interactive voice response or web system , and stratified by site , to placebo or subcutaneous peginterferon beta-1a 125 g once every 2 weeks or every 4 weeks .